Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge?
John Niederhuber named NCI chief operating officer; the surgeon was asked to leave two previous positions.
Cancer death rate dropping 1.1 percent a year, annual report finds.
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - ACOG says it will no longer accept federal funding
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- In The Headlines: Late poet Andrea Werblin Reid’s husband talks about publishing her final collection about dying from ovarian cancer